When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Failed to batch ingest runs: langsmith.utils.LangSmithError: Failed to POST https://api.smith.langchain.com/runs/batch in LangSmith API. maximum recursion depth ...
Abstract: Return-Oriented Programming (ROP) attacks pose a significant threat to the control-flow integrity of Internet of Things (IoT) devices, which operate in resource-constrained environments with ...
Stack of recursive calls to the same function (which is impossible for this function) on a flamegraph in the Pyroscope. These stacks appear after profiling, often this stack appears in the middle of ...
Meta recently released a new video editing app for creators called Edits. The new app is designed to rival ByteDance’s CapCut, a popular short-form video-editing app used by many creators. Meta first ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback